Compare Fortinet Inc (FTNT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fortinet Inc trades at $183.21 (market cap $139.96B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Fortinet Inc is far larger — about 143.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Fortinet Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FTNT | MRVI | |
|---|---|---|
Market Cap | $139.96B | $972.90M |
Volume | 2,774,680 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $194.75 | $9.00 |
52-Week Low | $75.23 | $2.83 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $136.39B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $184.05, down 4.61% today, but maintains a bullish technical trend with strong fundamental performance. The company reported revenue of $6.80B in 2025 with a net income margin of 28.17%, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its leadership in AI-driven cybersecurity and robust platform demand, with the stock nearing its 52-week high.
The outlook remains positive given strong earnings beats and raised 2026 guidance, though high valuation ratios (P/E 67.41) and competitive pressures pose risks. Analyst consensus is mixed with 42% buy ratings, but a $160.24 price target suggests caution relative to the current price. Institutional interest is growing, supporting momentum.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
